Substituted 2-anilinopyrimidine derivatives as EGFR modulators

A compound of formula I:

• or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein:
• G is selected from substituted or unsubstituted 1H-indol-3-yl, substituted or unsubstituted 1H-indazol-3-yl, substituted or unsubstituted 2H-indazol-3-yl, and substituted or unsubstituted pyrazolo[1,5-a]-pyridin-3-yl, and substituted or unsubstituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl;
• X is selected from oxygen, sulfur, and methylene;
• R1 is selected from hydrogen, halogen, methyl, trifluoromethyl, and cyano;
• R2, R3, and R4 are the same or different and are independently selected from hydrogen, halogen, and trifluoromethyl;
• provided, however, when X is oxygen and all of R2, R3, and R4 are hydrogen, then said substituted or unsubstituded 1H-indol-3-yl is
• and G is not pyrazolo[1,5-a]-pyridin-3-yl;
• R5 is selected from lower alkyl, optionally substituted 3- to 6-membered heterocyclyl, R7R8N-(lower alkyl), and R7R8N-(cycloalkylalkyl), wherein R7 and R8 are the same or different and are independently selected from hydrogen and lower alkyl;
• and
• R6 is selected from lower alkoxy and lower alkyl.